Coya Therapeutics reports Q2 2026 results, updates ALSTARS trial and FTD plans
Coya said its first ALSTARS cohort has moved into a blinded extension phase and it still expects topline ALS data in early 2027, with cash reaching $43.2 million.
Coya Therapeutics reported financial results for the quarter ended June 30, 2026 and gave an update on its lead program, COYA 302, a combination biologic aimed at boosting regulatory T-cell activity and dampening monocyte and macrophage inflammation. COYA 302 pairs a proprietary low dose of interleukin-2 with CTLA-4 Ig and is being developed as a subcutaneous treatment for ALS, frontotemporal dementia (FTD) and other neurodegenerative diseases.1
CEO Arun Swaminathan said enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, with the company still expecting to complete enrollment in 2026 and report topline data in the first quarter of 2027.1 He added that Coya intends to start a separate Phase 2 study of COYA 302 in FTD in the coming months.1
Among recent developments, Coya said patients in the first cohort of the ALSTARS trial have moved from the initial dosing period into a 24-week phase where they continue treatment under blinded conditions.1 The company also said COYA 302 received Fast Track Designation from the FDA for the treatment of ALS,1 a status meant to speed development and review of drugs for serious conditions with unmet medical need.1 President and Chief Medical Officer Fred Grossman said the blinded extension phase of the ALSTARS trial is now well underway.1
For the second half of 2026, Coya listed several expected milestones: completing ALSTARS enrollment, starting the FTD Phase 2 study, announcing biomarker data from a completed investigator-initiated FTD study, reporting additional single-cell proteomics data from completed ALS and Alzheimer's disease studies, and publishing in vivo data on a separate candidate, COYA 303, in an inflammatory animal model.1
On finances, Coya held $43.2 million in cash and cash equivalents as of June 30, 2026, which it said would support operations past the Phase 2 ALSTARS topline readout and extend into the latter part of 2027.1 Net loss for the quarter was $6.6 million, compared with $6.1 million in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.